Physician

Adam Attawit Rojan, MD

According to 2025 Medicare claims, Adam Rojan, MD (NPI: 1285837674) practices hematology/oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Hamilton, OH. This provider's primary affiliated billing organization is UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC (NPI: 1801840434; TIN: 311405915) and primary practice location at 45069-2509.

Rojan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 109 traditional Medicare patients, billed 512 HCPCS/CPT codes, and received $37,937 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 184 prescription claims across 57 beneficiaries totaling $252,894 in drug costs, led by Eliquis (Apixaban). DME data shows 29 claims. Open Payments data shows 1 records totaling $128. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $25,210 and ending at $37,937. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $165,160 and ending at $252,894. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	105	359	$25,210
2016	91	302	$20,804
2017	181	656	$44,832
2018	159	489	$31,464
2019	176	483	$32,121
2020	193	717	$47,056
2021	155	539	$41,391
2022	144	308	$26,740
2023	93	269	$25,552
2024	109	512	$37,937

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	28	164	$165,160
2016	53	209	$13,878
2017	87	517	$303,326
2018	94	566	$652,661
2019	70	529	$431,421
2020	77	536	$562,806
2021	89	567	$979,076
2022	63	240	$485,280
2023	55	160	$137,500
2024	57	184	$252,894

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	81	$7,341
2016	N/R	12	$382
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	74	$8,485
2020	N/R	33	$3,293
2021	N/R	N/R	N/R
2022	N/R	12	$421
2023	N/R	N/R	N/R
2024	N/R	29	$1,160

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	38	40	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	48	169	$106
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	17	26	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	49	127	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	46	132	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	19	690	$13,594
Prochlorperazine Maleate	Prochlorperazine Maleate	38	547	$756
Oxycodone Hcl	Oxycodone Hcl	21	411	$432
Dexamethasone	Dexamethasone	19	331	$300
Prednisone	Prednisone	11	300	$16

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$935
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$128	Intera Oncology, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Attawit Rojan, MD?

Tedicare shows public-source Medicare data for Adam Attawit Rojan, MD (NPI 1285837674), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Attawit Rojan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Attawit Rojan, MD?

Adam Attawit Rojan, MD is linked to UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC (billing NPI 1801840434) in the available physician profile data.

Does Adam Attawit Rojan, MD have Open Payments data?

Adam Attawit Rojan, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.